• Z-YVAD-FMK: Unlocking Caspase-1 Inhibition for Pyroptosis Re

  2026-07-27

  Explore how Z-YVAD-FMK, a potent caspase-1 inhibitor, enables precise dissection of pyroptosis and inflammasome signaling. Discover unique scientific insights and protocol guidance for apoptosis and cancer research.

• Sulfo-NHS-LC-Biotin: Protocol and QC for Surface Protein Lab

  2026-07-27

  Sulfo-NHS-LC-Biotin enables selective, irreversible biotin labeling of primary amines on proteins, especially useful for cell surface protein biotinylation where aqueous, membrane-impermeable reagents are required. It is not suitable for reversible or intracellular labeling workflows, making it ideal for extracellular detection, purification, or immobilization applications.

• CLK2 Inhibition Overcomes Platinum Resistance in Ovarian Can

  2026-07-26

  This study identifies Cdc2-like kinase 2 (CLK2) as a key driver of platinum resistance in ovarian cancer by enhancing DNA repair via BRCA1 phosphorylation. Targeting CLK2 offers a mechanistically validated approach to restoring platinum sensitivity, with implications for advancing alternative splicing and exon-skipping research.

• Demethyleneberberine: Applied Workflows in Inflammation and

  2026-07-25

  Demethyleneberberine (DMB), a metabolite of berberine, enables robust, mechanism-driven research across inflammation, neurodegeneration, and cancer models. This article details protocol-ready workflows, troubleshooting strategies, and novel insights from recent literature for maximizing DMB’s performance in preclinical and translational settings.

• IAM LC vs LEKC: Advances in Drug–Membrane Partitioning Analy

  2026-07-24

  This study provides a direct comparison between immobilised artificial membrane liquid chromatography (IAM LC) and liposome electrokinetic capillary chromatography (LEKC) for predicting drug partitioning and pulmonary permeability. The findings highlight the differential strengths of each method and offer practical guidance for researchers evaluating drug transport across biological membranes.

• Macrophage EV miR-660 Drives Breast Cancer Metastasis via KL

  2026-07-24

  This study uncovers how microRNA-660, delivered by tumor-associated macrophage extracellular vesicles, accelerates breast cancer progression by targeting KLHL21 and activating NF-κB signaling. The findings highlight a novel intercellular communication axis in the tumor microenvironment, providing mechanistic insight into metastatic regulation.

• WM-8014 for Reproducible KAT6A Inhibition in Cancer Biology

  2026-07-23

  This article explores how WM-8014 (SKU A8779) addresses key experimental challenges in cell cycle arrest, senescence induction, and epigenetic drug target research. Grounded in peer-reviewed evidence and practical workflows, it guides researchers on robust experimental design, protocol optimization, and reliable vendor selection for histone acetyltransferase inhibition.

• Metal-Ion Chelating l-Phe Nanostructures Boost ICB in Tumors

  2026-07-23

  This study introduces metal-ion-chelating L-phenylalanine nanostructures that, in combination with short-term starvation, reprogram the breast tumor microenvironment to overcome immune suppression and enhance the efficacy of immune checkpoint blockade (ICB). The findings reveal a biophysical mechanism for dendritic cell activation and offer a foundation for improved immunotherapy strategies.

• Masitinib (AB1010): Technical Use in KIT/PDGFR Inhibition Wo

  2026-07-22

  Masitinib (AB1010) is a selective tyrosine kinase inhibitor optimized for DMSO-based workflows targeting KIT, PDGFRα, and PDGFRβ. It is particularly useful in research on cancer (notably GIST), mastocytosis, and inflammatory diseases where precise kinase inhibition is required. It should not be used in protocols requiring aqueous or ethanol solubility, nor for broad-spectrum kinase inhibition.

• Structure-Based Screening Identifies NSP15 Inhibitors for SA

  2026-07-22

  This study employed a structure-based virtual screening approach to identify potent natural product inhibitors of NSP15, a viral endoribonuclease critical to SARS-CoV-2 immune evasion. The discovery of thymopentin and oleuropein as high-affinity, stable NSP15 inhibitors provides new directions for antiviral research and drug development.

• Cl-Amidine Trifluoroacetate: PAD4 Inhibition and Translation

  2026-07-21

  This thought-leadership article explores the strategic deployment of Cl-Amidine (trifluoroacetate salt) as a selective PAD4 inhibitor in translational research. By dissecting mechanistic insights into PAD4-driven epigenetic and immune processes, it bridges foundational evidence from cancer and inflammatory disease models with actionable guidance for researchers. Drawing on recent discoveries in chronic myeloid leukemia and sepsis, the article maps the competitive landscape, protocol strategies, and outlook for PAD4 inhibition as a pivot point in disease modeling and therapeutic innovation.

• Estrogen Receptor–Autophagy Axis Protects Organs in Perimeno

  2026-07-21

  This study elucidates how estrogen receptor signaling and autophagy collaborate to protect the heart, aorta, and kidneys during perimenopausal aging. By integrating human cohort data, mouse models, and network pharmacology, the research demonstrates that estrogen’s organ-protective effects depend on receptor-mediated autophagy activation, offering new insight for precision hormone therapy.

• Reversine and Aurora Kinase Inhibition: Mechanistic Insights

  2026-07-20

  Explore the molecular mechanisms of Reversine as an Aurora kinase inhibitor, with a unique focus on mitotic checkpoint disassembly and practical assay optimization. This in-depth article offers new perspectives for cancer cell proliferation inhibition and apoptosis induction research.

• APEX2 Regulates TERT Expression via DNA Repeat Elements in h

  2026-07-20

  A new study demonstrates that APEX2, but not APEX1, is essential for efficient TERT gene expression in human embryonic stem cells by acting on repetitive DNA elements like MIRs. These insights expand our understanding of telomerase regulation and have implications for stem cell biology and cancer research.

• Meropenem: β-Lactam Antibiotic Carbapenem in Resistance Work

  2026-07-19

  Meropenem’s ultra-broad spectrum and reliable activity against Gram-negative and Gram-positive bacteria make it a gold standard for resistance modeling in the lab. This article unpacks stepwise protocols, troubleshooting insights, and cutting-edge innovations—anchored by recent transmission studies—to help researchers maximize reproducibility in septicemia and carbapenem-resistance research.

8436 records 4/563 page Previous Next 12345 下5页 Last page